Please login to Zacks.com or register to post a comment.
They're hand-picked from the list of Zacks Rank #1 Strong Buys. Our experts predict that their prices will jump the soonest.
Today, you can see them free.
| No Recent Quote currently available |
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
| Company Name | Symbol | %Change |
|---|---|---|
| SCIENTIFIC L | SCIL | 8.00% |
| FEDERAL MOGU | FDML | 6.78% |
| SUMMER INFAN | SUMR | 6.62% |
| NEW ORIENTAL | EDU | 6.53% |
| RADIANT LOGI | RLGT | 5.85% |
Please login to Zacks.com or register to post a comment.
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
Leading medical technology firm Becton, Dickinson and Company ( BDX - Analyst Report ) recently revealed that it has accomplished the takeover of Safety Syringes, Inc. The monetary terms of the acquisition were not disclosed.
Safety Syringes was a privately held company based in California which focuses on creating anti-needlestick instruments for prefilled syringes.
Becton Dickinson stated that it was enthusiastic about the takeover. The offerings of Safety Syringes would align with the interests of the company by enhancing its focus on high value products and safety of healthcare staff. The takeover represents Becton Dickinson’s commitment toward innovative offerings and strengthens its role on safety know how.
Becton Dickinson believes that the takeover will be dilutive, in a very minor way, to its earnings for fiscal 2013. The acquisition will not affect its earlier released guidance for fiscal 2013.
We remain cautious about Becton Dickinson due to the lack of major short-term catalysts. The rising demand for safety-needle products (with higher price points and margins) was the primary driver of the company’s past growth. This is not expected to continue, given that the U.S. market is already largely penetrated.
On the positive side, Becton Dickinson’s preeminent global healthcare products franchise is partly insulated from volatile macroeconomic conditions and structural deficiencies elsewhere in the healthcare delivery field.
Becton Dickinson faces a wide range of competitors, including Baxter International ( BAX - Analyst Report ) in certain niches, in each of its three business segments. Our Neutral recommendation is supported by a short-term Zacks #3 Rank (Hold).
Read the full Analyst Report on BDX
Read the full Analyst Report on BAX